Published 13 days ago • loading... • Updated 13 days ago

Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations

Mabwell will present clinical study results for its Nectin-4-targeting ADC, BFv, at the 2026 American Society of Clinical Oncology Annual Meeting, including Phase Ib/II data for urothelial carcinoma and Phase II data for MIBC.
An innovation-driven biopharmaceutical company with a fully integrated industry chain, Mabwell maintains a mission to "Explore Life, Benefit Health" and a vision of "Innovation, from Ideas to Reality."
The Phase Ib/II clinical study of BFv for advanced urothelial carcinoma enrolled 52 patients, reporting an overall objective response rate of 83.0% and a disease control rate of 89.4%.
BFv has secured FDA Fast Track Designation for three indications, Orphan Drug Designation for one, and Breakthrough Therapy Designation from the CDE of the National Medical Products Administration for two.
Interim analysis for three Phase III clinical trials is planned for 2026, with applications for pre-NDA meetings expected for submission to the Center for Drug Evaluation under the National Medical Products Administration.

Insights by Ground AI

40 Articles

Bennington Banner

+39 Reposted by 39 other sources

Center

Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations

SHANGHAI, May 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American Society of…

13 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year